PAUL ESTRADA: Open Payments
NPI 1659708840 · WINTER HAVEN, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,121 in 117 payments from 15 companies in 2025. Trend: 2023 $2,022 · 2024 $1,809 · 2025 $2,121
Food & beverage: $2,121
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 37 | $527 |
| Axsome Therapeutics, Inc. | 16 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $261 |
| ABBVIE INC. | 8 | $205 |
| Neurocrine BioSciences, Inc. | 8 | $195 |
| Alkermes, Inc. | 15 | $182 |
| Janssen Pharmaceuticals, Inc | 1 | $125 |
| Lundbeck LLC | 5 | $120 |
| Tris Pharma Inc | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
Products named: REXULTI, Auvelity, CAPLYTA, VRAYLAR, INGREZZA, ABILIFY MAINTENA, SPRAVATO, LYBALVI.
Industry payments across FL — which companies pay providers there.
